Drug Type Small molecule drug |
Synonyms 复方利血平氨苯蝶啶, O号 |
Action inhibitors, blockers |
Mechanism NCC inhibitors(Thiazide-sensitive sodium-chloride cotransporter inhibitors), Sodium channels blockers, VMAT2 inhibitors(Synaptic vesicular amine transporter inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhaseApproved |
First Approval Date China (04 Aug 2015), |
Regulation- |
Molecular FormulaC7H8ClN3O4S2 |
InChIKeyJZUFKLXOESDKRF-UHFFFAOYSA-N |
CAS Registry58-93-5 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Hypertension | China | 04 Aug 2015 |